autoimmune diseases
Autoimmune disease clinical trials address conditions in which the immune system mistakenly attacks the body's own tissues β€” a category encompassing over 80 distinct diseases affecting approximately 8% of the global population. Shared immunological mechanisms across conditions have enabled cross-indication development: agents proven in rheumatoid arthritis (TNF inhibitors, JAK inhibitors, IL-6 inhibitors) are systematically evaluated in related conditions including ankylosing spondylitis, psoriatic arthritis, and IBD.
Cutting-edge trials investigate CAR-T cell therapy for severe refractory autoimmune diseases β€” with early results showing sustained drug-free remissions in SLE and systemic sclerosis β€” telitacicept for overlapping B-cell-driven autoimmunity, BTK inhibitors as precision tools for B-cell-mediated conditions, and tolerance induction protocols for type 1 diabetes and transplant acceptance. Precision medicine biomarkers (cytokine profiles, autoantibody panels, interferon signatures) are increasingly used to enrich trial populations.
Autoimmune trials span diverse specialists β€” rheumatologists, neurologists, gastroenterologists, nephrologists β€” reflecting the organ-system specificity of individual conditions.